Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8299587 | 0.82 | CYP3A4 (0.52) | BRD4CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8299628 | 0.81 | BRD4 (0.45) | BRD4CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8300613 | 0.78 | BRD4 (0.60) | BRD4 | |
| SCHEMBL8789567 | 0.76 | BRD4 (0.46) | BRD4CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL9375685 | 0.76 | DRD2 (0.49) | BRD4CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8790016 | 0.75 | BRD4 (0.47) | BRD4 | |
| SCHEMBL8790761 | 0.74 | TTR (0.50) | BRD4 | |
| SCHEMBL8791355 | 0.74 | ALDH1A1 (0.48) | BRD4 | |
| SCHEMBL8790036 | 0.74 | BRD4 (0.45) | BRD4 | |
| SCHEMBL12427418 | 0.74 | ALDH1A1 (0.51) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0429987-B1 | 5,11-Dihydro-6H-dipyrido[3,2-b:2',3'-e] [1,4]diazepines and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMA (US) | 1999-03-17 | — | — | EP | claimed |
| EP-0429987-B1 | 5,11-Dihydro-6H-dipyrido[3,2-b:2',3'-e] [1,4]diazepines and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMA (US) | 1999-03-17 | — | — | EP | disclosed |